Gaudium IVF and Women Health shares hit record high ahead of Q3 results; here's how it is performing vs IPO issue price

The stock rose as much as 17.35% to ₹99.75 apiece, its record high, on the National Stock Exchange (NSE).

The scrip settled 10.65% higher at ₹94.05 per share, with a market capitalisation of ₹684.56 crore.

"A meeting of the Board of Directors of Gaudium IVF and Women Health Limited is scheduled to be held on Wednesday, March 18, 2026, to inter-alia, consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025," the company said.

How Gaudium IVF and Women Health is performing vs IPO issue price

The company's shares debuted at ₹83 apiece, a premium of 5.06% over the IPO issue price of ₹79 per share, on the NSE and the BSE on February 27. Currently, it is up 13.79% from the issue at the intra-day high level.

The initial share sale sought to raise ₹165 crore via a fresh issuance of ₹90 crore and an offer for sale of ₹75 crore by promoter Dr Manika Khanna.

The funds raised are intended to set up 19 new In Vitro Fertilisation (IVF) centres across the country, repay certain borrowings and corporate general purposes.

The initial public offering was subscribed 7.27 times.

Before the IPO, the company had mobilised ₹49.5 crore in the anchor round from investors such as Carnelian India Multi Strategy Fund, Sanshi Fund I, MERU Investment Fund PCC-CELL and Hornbill Orchid India Fund.

Gaudium IVF and Women Health provides IVF treatments in India and operates through a hub-and-spoke model. It has seven hubs and 28 spokes across multiple states.